- AstraZeneca's (AZN) and Bristol-Myers Squibb's (BMY) approved Type 2 diabetes treatment Onglyza was unexpectedly linked with a small rise in hospitalizations for heart failure - where the heart is unable to pump blood properly - in a large-scale two-year study. The problem affected 3.5% of patients vs 2.8% in a control group.
- However, Onglyza didn't increase the risk of "cardiovascular death, heart attack or stroke."
- The drug, along with Takeda's Nesina, wasn't associated with higher rates of inflammation of the pancreas or cancer, which had previously been a concern.
- Onglyza and Nesina work by inhibiting dipeptidyl peptidase-4, or DPP-4, in order to strengthen the body's ability to reduce high blood-sugar levels. (PR)
Mixed news for diabetes drugs
Sep 2 2013, 07:52 ET